BLACK DIAMOND THERAPEUTICS, INC. (BDTX) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current |
| Current obligations | 15.84M USD | Liabilities, Current |
| Cash and equivalents | 19.19M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 91.31M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $15.84M | $19.19M | $91.31M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $14.53M | $30.07M | $88.19M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $15.73M | $20.99M | $107.66M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $15.54M | $30.86M | $104.64M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $16.80M | $29.99M | $112.84M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $16.85M | $98.42M | $53.98M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $20.57M | $36.44M | $62.14M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $20.80M | $23.43M | $89.26M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $18.44M | $32.81M | $90.16M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $16.85M | $25.42M | $89.78M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $19.65M | $56.22M | $75.18M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $15.07M | $57.98M | $86.28M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $13.90M | $41.89M | $47.64M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $12.85M | $39.14M | $64.22M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $15.26M | $34.31M | $88.49M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $21.14M | $53.96M | $90.22M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $19.71M | $55.88M | $105.01M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $19.47M | $54.08M | $125.66M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $23.64M | $65.80M | $143.99M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $26.36M | $46.60M | $188.41M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $23.49M | $37.32M | $226.15M | (m) | (m) | (m) |
| 2021-03-31 | (m) | $18.70M | $14.11M | $275.95M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $14.22M | $34.60M | $280.46M | (m) | (m) | (m) |
| 2020-09-30 | (m) | $11.34M | $56.20M | $276.88M | (m) | (m) | (m) |
| 2020-06-30 | (m) | $6.14M | $63.98M | $140.50M | (m) | (m) | (m) |
| 2020-03-31 | (m) | $7.30M | $357.19M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $4.86M | $154.67M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | $78.66M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | $39.65M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | $44.72M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $2.58M | $51.66M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |